Sign in
TerminatedPhase 1

MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Key facts

Who runs it
University of Pennsylvania
Where
Philadelphia, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 1
People taking part
46 people enrolled
Started
24 Oct 2018
Ended
26 Mar 2024
Type of study
Interventional, 4 groups
Treatments tested
  • MOv19-BBz CAR T cells
  • Alpha Folate Receptor expression test
Record updated
26 March 2025
Why it stopped
This study was halted prematurely due to recruitment barriers

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Histologically confirmed persistent or recurrent stage II to IV high grade serous epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Disease can be platinum-sensitive or platinum-resistant
  • Failure of at least two prior chemotherapy regimens for advanced stage disease. Prior therapies against PD-1 or PDL-1 are permissible
  • Confirmation of tumor aFR expression (≥70% of tumor cells with ≥2+ aFR staining)
  • Subjects must have measureable disease as defined by RECIST 1.1 criteria
  • Patients with asymptomatic CNS metastases that have been treated and are off steroids are allowed. They must meet the following at the time of eligibility confirmation by physician-investigator:; No concurrent treatment for the CNS disease; No progression of CNS metastasis on brain MRI at screening; No evidence of leptomeningeal disease or cord compression
  • Patients ≥ 18 years of age
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Satisfactory organ and bone marrow function as defined by the following:; Absolute neutrophil count ≥ 1,000/μl ii. Platelets ≥75,000/μl iii. Hemoglobin ≥ 9 g/dL iv. Total bilirubin ≤ 2.0x the institutional normal upper limit unless secondary to bile duct obstruction by tumor v. Creatinine ≤ 1.5x the institutional normal upper limit vi. Albumin ≥2 vii. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5x the institutional normal upper limit viii. Cardiac ejection fraction of ≥40%
  • Blood coagulation parameters: PT such that international normalized ratio (INR) is ≤ 1.5 and a PTT ≤ 1.2 time the upper limit of normal unless the patient is therapeutically anti-coagulated for history of cancer-related thrombosis and has stable coagulation parameters
  • Provides written informed consent
  • Subjects of reproductive potential must agree to use acceptable birth control methods, as described in protocol Section 4.3

Who cannot take part

  • Participation in a therapeutic investigational study within 4 weeks prior to eligibility confirmation by physician-investigator, or anticipated treatment with another investigational product while on study. This refers to non-commercially approved investigational drugs different than those used in this protocol
  • Planned concurrent treatment with systemic high dose corticosteroids. Patients may be on a stable low dose of steroids (<10 mg daily equivalent of prednisone). Corticosteroids treatment as anti-emetic prophylaxis on the day of lymphodepleting chemotherapy administration is allowed per institutional guidance. The use of topical and/or inhaled steroids are not exclusionary
  • Patients requiring supplemental oxygen therapy
  • Prior therapy with lentiviral gene modified cells
  • Any ascites requiring therapeutic drainage within 4 weeks prior to eligibility confirmation by physician-investigator
  • High grade serous ovarian, fallopian, or primary peritoneal cancer that is platinum refractory, defined as disease that has clinical or radiographic progression on platinum-based chemotherapy, as per the discretion of the treating physician
  • Active invasive cancer other than ovarian cancers. Patients with active non-invasive cancers (such as non-melanoma skin cancer, superficial cervical and bladder cancer) are not excluded
  • HIV infection
  • Hepatitis B or hepatitis C infection
  • Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to >/= 10 mg of prednisone. Patients with autoimmune neurologic diseases (such as multiple sclerosis) will be excluded
  • Patients with active and uncontrolled infection
  • Presence of any other condition that may increase the risk associated with study participation or may interfere with the interpretation of study results, and, in the opinion of the physician-investigator, would make the patient inappropriate for entry into the study
  • History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40)
  • Patients with symptomatic CNS metastases are excluded
  • Pregnant or breastfeeding women

Where in United States

  • University of Pennsylvania Health SystemPhiladelphia, United States

About the trial

What the trial wants to find out

Phase I study to establish safety and feasibility of intraperitoneally administered lentiviral transduced MOv19-BBz CAR T cells with or without cyclophosphamide + fludarabine as lymphodepleting chemotherapy

The 4 groups in the trial

  • Cohort 1: MOv19-BBz CAR T cells without chemoTreatment being tested

    Cohort 1: (n= 3 to 6 subjects): Single infusion of 1-3x107 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 without lymphodepleting chemotherapy.

    Treatment: MOv19-BBz CAR T cells and Alpha Folate Receptor expression test

  • Cohort 2: MOv19-BBz CAR T cells after chemoTreatment being tested

    Cohort 2: (n= 3 to 6 subjects): Single infusion of 1-3x107 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 beginning 3 days (+/- 1 day) after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.

    Treatment: MOv19-BBz CAR T cells and Alpha Folate Receptor expression test

  • Cohort 3: MOv19-BBz CAR T cells after chemoTreatment being tested

    Cohort 3: (n=3 to 6 subjects): Single infusion of 1-3x108 lentivirally transduced MOv19-BBz CAR T cells on day 0 beginning 3 days (+/- 1 day) after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.

    Treatment: MOv19-BBz CAR T cells and Alpha Folate Receptor expression test

  • Cohort-1: without chemo;only if dose de-escalation requiredTreatment being tested

    Cohort -1: (n= 3 to 6 subjects): Single Infusion of 1-3x106 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 without lymphodepleting chemotherapy. Up to 6 subjects will be infused in Cohort -1 with ≤ 1 DLT/6 subjects to establish the MTD.

    Treatment: MOv19-BBz CAR T cells and Alpha Folate Receptor expression test

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase I Clinical Trial of Adoptive Transfer of Autologous Folate Receptor - Alpha Redirected T Cells for Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Publications
Record updated
26 March 2025